Affordable Access

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy

Authors
  • rotolo, ramona
  • leuci, valeria
  • donini, chiara
  • cykowska, anna
  • gammaitoni, loretta
  • medico, giovanni
  • valabrega, giorgio
  • aglietta, massimo
  • sangiolo, dario
Publication Date
Jun 11, 2019
Source
MDPI
Keywords
Language
English
License
Green
External links

Abstract

T, natural killer (NK), NKT, or cytokine-induced killer (CIK) cells. The intrinsic CAR-independent antitumor activities, safety profile, and ex vivo expansibility of these alternative immune effectors may favorably contribute to the clinical development of CAR strategies. The proper biological features of innate immune response effectors may represent an added value in tumor settings with heterogeneous CAR target expression, limiting the risk of tumor clonal escape. All these properties bring out CAR engineering of alternative immune effectors as a promising integrative option to be explored in future clinical studies.

Report this publication

Statistics

Seen <100 times